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Summary.-A comparison was made between the cells responsible for demonstrable
activity against MSV antigens, using both in vivo and in vitro assays. Similar
cells (in terms of size and sensitivity to anti-theta serum) were detected in both
assays. However, while lymphoid cells from animals at all stages post-MSV
infection were active in protecting irradiated mice from the lethal effect of induction
of MSV sarcomata, cells from animals at early stages post-MSV infection (when the
tumour was in a progressive phase of growth) were not active in the in vitro assay.
By manipulation of the in vivo assay conditions a situation was observed in which
cells from " progressor animals " were able to suppress both the in vitro and in
vivo activity of regressor lymphoid cells. The potential physiological role of this
cell type is discussed.
PREVIOUS papers in this series
(Gorczynski, 1974 a, b, c), and work from
other laboratories (Fefer et al., 1968;
Hellstr6m and Hellstrom, 1969; Lamon et
al., 1972; Owen and Seeger, 1973) have
established that a correlation exists be-
tween the ability to detect, in various in
vitro assays, cell mediated immunity to
murine sarcoma virus (MSV) induced
sarcomata and the status of tumour
growth in the host animal. While the
tumour is in a regressing phase, or after
tumour regression, cells can be detected
which are capable of killing MSV tumour
cells, or recognizing antigens expressed by
those cells and then reacting in other
immunological tests. In these latter
assays (Gorczynski, 1974b, c; Halliday,
1972) the reactive cells are T lymphocytes.
When the tumour is in a progressive
phase of growth such effector cells are
detected less readily. Indeed, there is
evidence that serum factors exist at this
time in progressor animals which can
block the in vitro assays of cell mediated
immunity (Hellstrom and Hellstrom, 1969,
1970; Halliday, 1972). It has also been
reported that such " progressor animals "
have in their spleen and lymph node organs
a cell type capable of suppressing even the
nonspecific T lymphocyte response to the
mitogen phytohaemagglutinin, PHA
(Gorczynski, 1974c).
Despite the attention paid to develop-
ing in vitro techniques for studying
tumour immunity in animal systems, little
is known from direct studies ofthe relative
importance of the cells so detected, to the
in vivo growth of the tumour. In the
MSV system it has been reported that
sublethally irradiated mice inoculated
with MSV die from the progressive tumour
growth unless they are also inoculated
with immune cells or serum from regressor
animals. Subsequent work suggested that
the cells active in such adoptive transfer
systems were T lymphocytes (Gorczynski,
1974a; Fefer, 1969). It was thus of great
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interest to examine whether these cells
were related to the cells detected with in
vitro techniques. In addition, we won-
dered whether cells capable of suppressing
in vitro immunity might also be capable of
suppressing activity in this in vivo pro-
tection assay.
The data presented below suggest that
the in vitro assays analysed in earlier
reports probably do indeed detect T
lymphocytes of relevance to the in vivo
growth pattern of the tumour. Some
evidence is presented to suggest that the
blocking seen in vitro (Gorczynski, 1974c)
may play a physiological role in allowing
tumour growth in vivo.
MATERIALS AND METHODS
Mice.-Male BALB/C mice from the
ICRF breeding unit at Mill Hill were used
throughout.
Tumours.-Sarcomata were induced in
3-4 week old BALB/C mice by injection of
0-1 ml of an MSV tumour homogenate into
the thigh. The tumour in the mice normally
appears at 7 days, progresses to 12 days and
then begins to regress, disappearing com-
pletely by 21 days (Fefer et al., 1968). Mice
at 9-12 days post-MSV are referred to as
progressors, and 18 days and upwards post
MSV as regressors.
Irradiation of mice.-Mice were given 700
rad of x-irradiation from a 60Co source at a
dose rate of 24 rad/min. All such mice were
used at 6 weeks of age and all received
5 x 105 bone marrow cells injected intra-
venously immediately after irradiation to
protect the animals from the potentially
lethal effect of bone marrow aplasia. All
subsequent virus and cell inoculation into
these animals was performed within 3 h
ofirradiation.
Measurement of tumour volumes.-The
dimensions of the developing tumours were
measured at different times and tumour
volumes calculated from the formula Volume:
0-4 (ab)2, where "a" is the maximum
diameter of the tumour, and "b is the
diameter at right angles to " a" (Attia, De
Ome and Weiss, 1965).
Cell preparation.-Spleen cells were pre-
pared by teasing the respective tissues apart
in ice-cold phosphate buffered saline (PBS).
Large fragments were allowed to settle out
and the suspension was centrifuged at 200 g
for 10 min at 4°C. Red cells in the spleen
preparations were lysed according to the
method of Boyle (1968), using Tris buffered
ammonium chloride. Before inoculation of
cells into animals, the cells were suspended in
PBS with 0-1% bovine serum albumin
(BSA). Before assaying in vitro (see below),
cells were suspended in MEM leucine-free
medium, supplemented with glutamine, non-
essential animo acids, and penicillin and
streptomycin. All cell counts referred to
below are viable cell counts (determined by
trypan blue dye exclusion) unless otherwise
stated.
Stimulation of protein synthesis.-The
essential features of this assay are described
in detail elsewhere (Rosenberg et al., 1972;
Gorezynski and Rittenberg, 1974).
In all ofthe experiments described herein,
where immunity to MSV antigens was inves-
tigated in vitro, the antigen preparation used
in the in vitro test was a sample of disrupted
whole MSV virus, a kind gift from Dr R. A.
Knight. This has been characterized in
terms ofits ability to stimulate MSV-immune
lymphoid cells in earlier publications
(Gorczynski, 1974b, c). The final concen-
tration of MSV antigen used in the test was
1-0 mg/ml. The final data from these assays
are routinely expressed as a percent stimula-
tion (with 95% confidence limits) of protein
synthesis in the presence of antigen (com-
pared with the degree of synthesis in the
absence of antigen). All groups (with and
without antigen) were set up in triplicate.
Velocity cell sedimentation.-Velocity cell
sedimentation was performed as described
previously (Miller and Phillips, 1969). A
sterile glass sedimentation chamber, 11-0 cm
in diameter, was used throughout. Cells
were loaded in0.3% BSA in PBS; a 0.6-2.0%
BSA in PBS buffered step gradient was used.
All separations were performed for 3 h at 4°C.
Antisera and treatment of cells with
antisera.-The preparation and testing of a
heterologous rabbit anti-mouse brain asso-
ciated theta antigen (Br anti 0) and an anti-
mouse immunoglobulin (anti-Ig) are described
in detail elsewhere (Gorczynski, 1974a).
By the criteria described in this com-
munication, the Br anti-6 was a functional
anti-T cell reagent, and the anti-Ig an anti-B
cell reagent. Cells to be treated with either
antiserum and/orcomplement were suspended
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to a final concentration (in serum or comple-
ment) of 10 x 106 cells/ml. The antisera
and complement were diluted for use in PBS
with 0-1% BSA. Br anti-0 was used at a
final concentration of 1/15 and anti-Ig at a
final concentration of 1/10. Cells were
incubated in antiserum for 90 min at 40C,
centrifuged at 200 g for 5 min at 40C and
resuspended in guinea-pig complement (dilu-
ted 1/10 in PBS with 0-1% BSA). The cells
were incubated for 45 min at 370C in a
humidified CO2 containing atmosphere and
then washed twice as above. The final cell
pellet was resuspended in the medium
appropriate for the test required and anlysed
as described in the text. Typical data to
demonstrate the specificity of the two anti-
sera are shown in Table I.
RESULTS
Correlation of anti-MSV activity in vitro
with ability to protect sublethally irradiated
MSV inoculated mnice
Earlier publications have shown that
cells from MSV regressor animals can be
stimulated to enhanced protein synthesis
in vitro by MSV antigens, and can also
protect sublethally irradiated MSV inocu-
lated mice from the lethal effects of
progressive tumour growth (Gorezynski,
1974a, b). In contrast, it was shown that
spleen cells taken from MSV progressor
mice were unable to respond in the in
vitro assay used without prior manipula-
tion to remove a cell population which
nonspecifically suppressed T cell responses
in the spleens of those animals
(Gorczynski, 1974c). In a preliminary
examination of the correlation between
in vitro and in vivo assays for
immunity in this system, we investigated
whether there was any difference in the
relative abilities of spleen cells taken from
mice at different times post MSV to
respond in the two assays described.
Mice 24-27 days old were singly
injected with MSV at weekly intervals
over a period of several weeks. Four mice
(given MSV 31, 24, 17 and 10 days
earlier) from each group were sacrificed,
together with 4 non-infected mice (whose
age was approximately a mean of that of
the other experimental mice), and the
spleens within each group were pooled
and used to make single cell suspensions.
Aliquots of each suspension were assayed
in vitro for their ability to be stimulated
by MSV antigens. In addition, 10 x 106
cells of each type were given intraperi-
toneally in 0-5 ml PBS (with BSA) to
6-week old mice which had been irradiated
and inoculated with MSV. Two control
groups consisted of irradiated mice not
given MSV, and irradiated mice given
MSV and no spleen cells. Six mice were
used for each group and the animals were
examined daily for tumour growth and
mortality. The data for this experiment
are shown in Table II.
As already described, it is clear that
unfractionated normal spleen cells, or cells
from progressor animals, were unable to
respond to the antigen tested in the in
TABLE L.-Specificity of Br anti-O and anti-Ig serumfor killing T or B cells
Per cent stimulation of protein synthesisb
Antiseruma ,A-_ _-__
treatment PHA (1 jtg/ml)c LPS (10 /tg/ml)c
None 176±36 65±17
Br anti-0 21+24 82±11
Anti-Ig 252±30 4± 8
(a) Spleen cells were obtained from a pool of 6, 10-week old BALB/c mice. Cells were incubated in
either medium only or in either of the two antisera, as described in the Materials and Methods section,
and then all were treated with guinea-pig complement. Cultures were set up containing 4 x 106 cells as
shown.
(b) Arithmetic mean (with 95% confidencelimits) determined from 3 cultures per group (with and without
antigen).
(c) 20 1l of mitogen were added to the cultures as described in the Materials and Methods section. The
final concentration of mitogen present is shown in brackets.
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TABLE II.-Correlation between Cells Active in in vivo and in vitro Tests of
Cells useda
in
test
None
None
Normal spleen
10 days post MSV
17 days post MSV
24 days post MSV
31 days post MSV
Immnunity to MSV
Per centb Protection of sublethally irradiated MSV injected mice
stimulation --
of protein MSVC No. of miced Day of peake Day of tumourf Survivalg
synthesis inoculated with tumours tumour volume regression at 25 days
5±11
-2± 8
40±15
56± 13
49±21
±
±
±
±
-I-
±
0/6
6/6
6/6
6/6
6/6
6/6
6/6
11(2-4)
11(2 *3)
12(1.9)
11(1*9)
11(1 *8)
11(2 *0)
16
18
17
17
6/6
0/6
0/6
5/6
6/6
6/6
6/6
(a) Cells were pooled from 4 animals for each group as described in the text. For the in vitro test
4 x 106 cells were cultured in glass tubes, with or without MSV antigen. For the in vivo test 10 x 106 cells
were inoculated intraperitoneally into sublethally irradiated mice previously injected as described under (c).
(b) Arithmetic mean, with 95% confidence limits, using 3 cultures per group.
(c) All mice were 6 weeks of age, irradiated with 700 rad and injected with 5 x 105 adult bone marrow
cells. MSV was also inoculated into the groups shown; 6 mice were used per group.
(d) Number of mice developing palpable tumours at some time after MSV inoculation compared with
number of mice per group.
(e) Day when the mean tumour volume (arithmetic mean) in the group was greatest. The mean tumour
volume on this day is shown in brackets.
(f) Day when more than 50% of the mice in the group had no palpable tumours.
(g) Number of mice alive, compared with the number injected at the day shown.
vitro assay. In contrast, cells from all
ages of regressor animals seemed fully
capable of responding. In comparison
with the in vitro data, markedly different
results were obtained when the in vivo
test was used. It was apparent that
animals at all stages were equally active
in protecting the irradiated MSV injected
mice. No difference was subsequently
found even when cells taken from animals
at different times post MSV were titrated
for their effectiveness in protection
(Gorczynski, unpublished data).
Analysis ofthe sedimentation characteristics
of cells active in two assays of immunity to
MSV
There are two immediately apparent
reasons for the discrepancies observed
above. Firstly, the actual effector cell
types active in the two assays may not be
the same. Secondly, the cells responsible
for the lack of activity seen in unfrac-
tionated progressor spleen cells assayed in
vitro may have little physiological signi-
ficance in the intact animal, or may not be
able to function after adoptive transfer.
Since fairly detailed studies have already
been performed to characterize the effector
cells in the in vitro assay in terms of their
size and sensitivity to different antisera
(Gorezynski, 1974b), we investigated
whether there was any difference in the
cells responsible for activity in vitro and
in vivo which could be revealed by either
of these methods.
On separate occasions 5 x 108 spleen
cells were pooled from 4 animals given
MSV at the times shown in the Fig. and
fractionated as described in the Materials
and Methods section. After 3 h, 30 ml
fractions were collected, the cells per ml in
each fraction determined and the fractions
centrifuged at 200g for 10 min at 4°C.
Fractions were pooled as shown in the
Fig., the viable cellsrecovered determined,
and the cells assayed as follows:
For the in vitro assay 3% of the cells
of each fraction in 200 ,al ofMEM leucine-
free medium were pipetted into each of 6
culture tubes, 3 containing 20 ,ul of
medium and 3 containing 20 ,ul of MSV
antigen. Control cultures were set up with
unfractionated normal cells or test cells
(4 x 106 cells per tube). The cultures
were harvested after 18 h, as described in
the Materials and Methods section. For
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test). In all cases 6 animals were used per group. At each time of assay control groups included
animals irradiated and given no MSV (in this case survival was always 100%) and irradiated mice
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given MSV developed tumours at some time post infection.
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the in vivo assay, 5% of the cells of each
fraction were inoculated into mice pre-
viously irradiated and given MSV. Six
mice were used per group. Control groups
again consisted of mice given 10 x 106
unfractionated normal cells or test cells, in
addition to the two control groups
described in Table II.
The data for this experiment are
shown as a series of panels in the Fig. In
each case the upper part of each panel
shows the activity in the protein syn-
thesis assay. Test cells are shown as
closed circles and unfractionated cells
(normal-open circle, or test-closed circle)
are shown to the left of the panel. The
lower half of each panel shows the data
obtained using an in vivo assay. Survival
ofmice injected with cells ofthe individual
fractions is shown as a histogram-
again activity from unfractionated cells is
shown to the left of the Fig.
There are several features worthy of
note in this Fig. With regard to the
protein synthesis data, once again it was
seen that unfractionated normal or pro-
gressor spleen cells were unresponsive,
whereas regressor cells were fully respon-
sive in this test (Gorczynski, 1974b, c).
However, fractionated progressor spleen
cells did show activity, unlike fractionated
normal spleen cells (Gorczynski, 1974c).
There was a general tendency for activity
at early times post MSV to be expressed in
both large and small cells, whereas at
later times activity in large cells declined.
The in vivo protection data seemed to
explain the anomaly of Table II. Again,
when unfractionated cells were compared,
it seemed that progressor and regressor
cells were equally active and that there
was no good correlation with the in
vitro assay. However, upon fractionation,
it was apparent that the cell populations
active in these two assays in fact co-
sedimented. While this does not give
absolute proof of identity, it does suggest
that the reason for the anomaly referred to
above may have more to do with the
failure ofsuppression on adoptive transfer
ofprogressor cells, rather than a difference
in the effector cell types involved in the
two assays. We also observed some slight
protection with fractionated normal spleen
cells in vivo (panel a). This has been
referred to elsewhere (Gorczynski, 1974a;
Fefer, 1969), and is probably due to
normal T lymphocytes. In keeping with
this suggestion, the sedimentation charac-
teristics of the cells in the normal spleen
cell population capable of protection,
correlated well with these reported for
normal T lymphocytes (Miller andPhillips,
1970).
Effect of Br anti-6 on protection afforded by
regressor cells ofdifferent sizes
In an earlier report it was shown that
the cells in both normal and MSV regressor
animals which could protect irradiated
MSV inoculated mice, were sensitive to
Br anti-& serum and complement, and
were insensitive to anti-Ig serum and
complement (Gorczynski, 1974a). This
characteristic was also reported for those
cells capable of in vitro stimulation by
MSV antigens (Gorczynski, 1974b, c>.
Data presented in these reports and in the
Fig. indicate that after velocity sedimen-
tation activity in both in vitro and in vivo
assays is greatly enriched in the large cell
region of the gradient. Thus (see Fig.)
while the total activity profiles show a
relatively equal distribution of activity
between slow and fast sedimenting cells,
the activity on a per cell basis is increased
in the faster sedimenting cells (since there
are so few of these cells relative to the
numbers of small cells). In view of the
limitations in the sensitivities of the two
assays used, analysis of unfractionated
cells would probably not be fully informa-
tive with regard to the properties of
fractionated cells. In particular, if, say,
50% of the activity in large cells (which
themselves contribute a maximum of50%
of the total activity of unfractionated
cells) were insensitive to Br anti-0 serum
and complement, it is unlikely that either
of the assays used would detect as signi-
ficant the expected survival (25%) of the
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activity in unfractionated cells after such
antiserum treatment. Accordingly, we
investigated the relative sensitivities to
Br anti-C serum of the activity of frac-
tionated and unfractionated regressor
spleen cells, using both in vivo and in vitro
assays.
5 x 108 spleen cells from a pool of 6
mice given MSV 20 days before, were
sedimented for 3 h at 4°C, as described in
the Materials and Methods section. Cells
sedimenting in the regions 2-8-4 1 mm/h
(small cells) and 5-8-7-5 mm/h (large cells)
were pooled and centrifuged at 200 g for
10 min at 4°C. The populations were
resuspended in 5 ml PBS in 0-1% BSA and
the viable cells recovered determined.
Each population, together with unfrac-
tionated normal and immune (regressor)
cells, was then divided into two and one
halftreatedwithBranti-O and complement,
the other with medium and complement.
Equal numbers of viable cells recovered
after such treatment were then tested in
vitro for stimulation with MSV antigens
(2 x 106 cells per culture) or in vivo for
their ability to protect irradiated MSV
inoculated mice (4 x 106 cells per mouse).
The data for this experiment are shown
in Table III.
It is clear from this table that the
activity seen with both in vivo and in vitro
assays from small regressor cells, or from
unfractionated regressor cells, was com-
pletely abolished by treatment with Br
anti-C and complement. It seemed that
all of the large regressor cells responding
in vitro were also T lymphocytes. How-
ever, while Br anti-C and complement
reduced the in vivo activity of large
regressor cells, it was not clear that the
activity was wholly abolished. It may be
that the large T lymphoctyes were less
sensitive to Br anti-C than small T cells
(though the data from the in vitro assay
did not support this notion). An alter-
native explanation was that another cell
type, sedimenting in this region of the
gradient, was also active in the in vivo
assay but not in the in vitro assay.
Perhaps this cell is an " activated macro-
phage ", suggested by other workers as
TABLE III.-Effect of Br anti-O on Activity to MSV Antigens ofLarge and Small
Spleen Cellsfrom Regressor Animals
Per centb
stimulation
Cells useda of protein
in test synthesis
Normal spleen 24 10
"Unfractionated"
regressor cells 45+13
"Large "
regressor cells 30+ 7
Small "
regressor cells 41± 7
Br anti-0 treated
" unfractionated" 3+ 6
regressor cells
Br anti-0 treated
" large " -2+A 7
regressor cells
Br anti-0 treated
" small " 0+11
regressor cells
Activity in vivo
MSVC No. of miced Day of peake Day oftumourf Survival atg
inoculated with tumours tumour volume regression 25 days
0/6 6/6
+ 6/6 10(1.8) 0/6
+ 6/6 12(1-9) 0/6
+ 6/6
+ 6/6
+ 6/6
+ 6/6
+ 6/6
+ 6/6
11(1* 7)
12(1. 9)
11(1* 8)
11(1* 7)
12(1. 9)
18
16
17
6/6
5/6
6/6
0/6
2/6
0/6 11(1* 7)
(a) Preparation of cells and treatment with antisera are described in the text. For the in vitro assays
2 x 106 cells were used per culture. For the in vivo assay 4 x 106 cells were inoculated intraperitoneally.
(b), (c), (d), (e), (f) and (g) as for Table II.
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being important in anti-tumour activity
in vivo (Evans and Alexander, 1972).
Ability of progressor spleen cells to block
protection by regressor spleen cells
We have presented evidence to suggest
that the cells immune to MSV as detected
by in vitro stimulation assay may also be
the cells important in protecting sub-
lethally irradiated mice given MSV from
the lethal effects of progressively growing
sarcomata. However, while we could
easily demonstrate the presence of an
auxiliary cell type in progressor animals,
which blocked the observed in vitro
immunity seen from the spleens or lymph
nodes ofthese animals (Gorczynski, 1974c)
there was no obvious role for such a cell
type when we used the in vivo assay
described (Table II and the Fig.). While
it was certainly possible that the explana-
tion lay in the fact that the in vitro assay
was open to many non-physiological
artefacts, an alternative explanation was
that after adoptive transfer into these
sublethally irradiated recipients there was,
perhaps for a variety ofreasons, a reduced
likelihood of the cell-to-cell interaction
needed to witness the suppression seen in
vitro. In order to examine whether the
in vitro suppressor cells were related
physiologically to the tumour growth
status of the host mice (such cells were
found only in animals with progressively
growing tumours), we investigated the
effect ofadding a large excess ofprogressor
spleen cells to small numbers of regressor
cells before adoptive transfer into irradi-
ated recipients (given MSV). Since un-
fractionated progressor cells could them-
selves protect these animals (Table II and
Fig.) and since, at least in regressor
animals, the protection could be abolished
by treatment with Br anti-d and comple-
ment, we pretreated the cells added to the
regressor cells with Br anti-0 and com-
plement. In control groups Br anti-6
treated normal or regressor spleen cells
were also added to small numbers of
untreated regressor cells to investigate
their ability to affect the protection
afforded by untreated regressor cells.
Spleen cells were taken from mice
given MSV 10 or 24 days beforehand, as
well as from non-infected mice (age
matched to the 24-day post-MSV mice);
8 mice of each type were used to prepare
the 3 pools of cells. 8 X 108 cells of each
population were treated with Br anti-O and
complement, as described in the Materials
and Methods section; 50 X 106 of each of
the treated cell suspensions were then
injected, alone or in combination with
5 X 106 regressor spleen cells, into irra-
diated mice inoculated with MSV. Con-
TABLE IV.-Effect of Br anti-O treated Progressor Spleen Cells on Protection in vivo
Afforded by Regressor Spleen Cells
Cells useda
in test
Normal spleen (NS)
Progressor spleen (PS)
Regressor spleen (RS)
Br anti-0 NS
Br anti-0 PS
Br anti-0 RS
RS + Br anti-0 NS
RS + Br anti-0 PS
RS + Br anti-0 RS
MSVb
inoculated
+
+
+
+
+
+
+
No. of micee
with tumours
0/6
6/6
6/6
6/6
6/6
6/6
6/6
6/6
6/6
6/6
6/6
Time of peakd Time of tumoure
tumour volume regression
11(2-2)
9(2*6)
11(2-0) 17
11(1 8) 16
12(2-1)
9(2*0)
11(1* 9)
11(2-4) 15
12(2-0) 18
10(2- 3) 16
(a) Preparation and treatment of cells are described in detail in the text. When untreated cells were
tested 10 x 106 cells were injected per animal. When treated cells were tested 50 x 106 cells were injected
per animal, with or without 5 x 106 untreated regressor spleen cells.
(b), (c), (d), (e) and (f) as for (c) to (g) of Table II.
Survival atf
25 days
6/6
0/6
0/6
6/6
6/6
0/6
0/6
1/6
6/6
3/6
6/6
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trol groups investigated the protection
afforded by 10 x 106 untreated cells of
each type. The data for this experiment
are shown in Table IV.
As described in Table II, both pro-
gressor and regressor spleen cells (but not
normal spleencells) protectedtheirradiated
animals from the lethal effects of MSV
inoculation. Treatment with Br anti-O
serum and complement abolished the
activity seen in this assay. Equally
interesting was the observation that large
numbers of Br anti-O treated progressor
cells (but not similarly treated normal
cells orregressor cells) decreased the ability
of regressor spleen cells to protect these
animals. In additional experiments the
data suggested thatthe cells possessing this
activity in aBranti-O treated population of
progressor cells sedimented in the region of
thegradient containing cells of sedimenta-
tion velocity 4 5-6*4 mm/h (Gorczynski,
unpublished observations). Bothobserva-
tions concur with those reported earlier
for the suppressor cells active in vitro
(Gorczynski, 1974c). Analysis of the
sensitivity of these cells (active in vivo) to
anti-Ig serum has not proved possible in
view of the greater number of suppressor
cells needed to see activity in vivo (above
and Gorezynski, 1974c) and the overlap
with " active cells " in the gradient separa-
tion used.
DISCUSSION
Previous papers in this series have
shown that the spleens of MSV regressor
animals contain T lymphocytes capable of:
(i) protecting sublethally irradiated mice
from the now lethal effect of MSV inocu-
lation (Gorczynski, 1974a; Fefer, 1969); (ii)
responding to MSV antigens in vitro with
enhanced DNA and protein synthesis
(Gorezynski, 1974b).
Other workers have suggested that in
vitro assays in this system detect T cell
(Leclerc, Gomard and Levy, 1972), B
cell (Lamon et al., 1972) or macrophage
(Owen and Seeger, 1973) mediated im-
munity. Previous work, studying the
ability of cells and/or serum to protect
sublethally irradiated animals from pro-
gressive tumour growth (with ultimate
death ofthe host), suggested that both cell
mediated and humoral immunity may be
important (Fefer et al., 1968; Fefer, 1969;
Pearson, Redman and Bass, 1973). Sub-
sequent work supported both of these
findings (Gorczynski, 1974a), though it
was concluded that when limiting cell
numbers were injected the role of anti-
viral antibody in protection was greatly
reduced. Indeed, sera from all of the
animals used in the course of these
studies were examined throughout for
anti-viral antibody by Dr R. A. Knight,
with consistently negative results.
Hellstrom and Hellstrom (1969, 1970)
have suggested that during the progressive
phase of growth of the MSV induced
sarcoma, anti-tumour immunity in vivo is
blocked by factors in the serum, perhaps
antigen-antibody complexes (Sjogren et
al., 1971). The suggestion was made that
these blocking factors themselves provided
the environment which allowed tumour
growth in the face of anti-tumour directed
immunity (Halliday, 1972; Hellstrom and
Hellstrom, 1969,1970; Baldwin, Price and
Robins, 1972). In an analogous fashion,
it has been suggested that a cell which
blocks T lymphocyte activity in a non-
specific manner may be in some way
be responsible for tumour progression
(Gorczynski, 1974c). Both hypotheses
would gain much in credibility if their
physiological importance could be demon-
strated in a more direct fashion.
We have noted in this report that,
unlike their inability to respond using in
vitro assays, cells from progressor animals
were fully capable ofprotecting sublethally
irradiated mice inoculated with MSV
(Table II). Vhile this was an anomalous
finding with respect to the in vitro data,
more detailed examination of the reactive
cells in progressor and regressor animals
using the in vitro and in vivo assays ruled
out the possibility that the two assays were
not related. The cells active in each had
similar sedimentation characteristics
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(Fig.), and similar sensitivities to Br
anti-O serum and complement (Table III).
The latter observation was tempered by
the consistent finding that large cells in
the spleens ofMSV regressor animals were
inactive after Br anti-6 treatment using
the in vitro assay, but retained appreciable
activity in vivo (Table III). This is
perhaps best explained by suggesting that
sensitized antigen-specific T lymphocytes
may activate non-T cells (macrophages)
to kill tumour cells (Evans and Alexander,
1972), a possibility already suggested for
the MSV system by the work of Owen and
Seeger (1973) and Houchens et al. (1973).
If similar effector cell types are
responsible for activity in vitro and in vivo,
the anomalous behaviour of progressor
spleen cells in vitro may be due to an
inhibition of activity which has little
physiological significance, whether the
inhibition is specific (Hellstrom and
Hellstrom, 1969, 1970; Halliday, 1972) or
nonspecific (Gorczynski, 1974c). However,
the data of Table IV suggest an alterna-
tive explanation, namely, that in the
adoptive transfer system used to investi-
gate immunity in vivo, there is less
likelihood of the cell contact necessary
for inhibition, and this likelihood is
increased by merely increasing the number
of " suppressor " cells inoculated.
In a previous report, non-antigen
specific blocking of T cell mediated
immunity was reported in MSV progressor
mice (Gorczynski, 1974c). Blocking by
serum factors is ofan antigen specific type
(Hellstr6m and Hellstrom, 1969, 1970;
Halliday, 1972). It is quite feasible that
both types of suppression could be
encompassed within the same model,
perhaps even being caused by similar
molecules (Gorczynski et al., 1974). The
main difference between the two types of
suppression would then perhaps be caused
by the concentration of blocking factors
present. At present no evidence allows us
to make conclusive answers to such
questions. Indeed, there are as yet no
definitive data to show that " blocking "
in vivo is ofa specific ornonspecific nature,
or that it is related to the " blocking "
seen in vitro. Current work is engaged in
examining the relationship between speci-
fic and nonspecific suppression in vitro and
in vtvo.
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